http://www.ncbi.nlm.nih.gov/pubmed/22494945

Trends Mol Med. 2012 Apr 9. [Epub ahead of print]

PPARγ as a therapeutic target in cystic fibrosis.

Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM.

Source

Department of Pediatric Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands; Center for Molecular and Cellular Intervention, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Abstract

Cystic fibrosis (CF) is characterized by a proinflammatory pulmonary condition that may result from increased infections and altered intracellular metabolism in CFTR-deficient cells. The lipid-activated transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) has well-established roles in immune cell function and inflammatory modulation and has been demonstrated to play an important role in the heightened inflammatory response in CF cells. Here, we summarize current literature describing PPARγ-dependent alterations of CF cells and discuss the potential of PPARγ ligands for treating CF.